SciSparc stock soars after deal to gain controlling stake in Miza III Ventures

SciSparc Ltd. (NASDAQ:SPRC) shares surged 34.5% after the company announced a definitive agreement to acquire a controlling interest in Miza III Ventures Inc. (TSXV:MIZA.P). Under the terms, SciSparc will transfer its advanced clinical-stage pharmaceutical portfolio, valued at approximately $11.6 million, and a 51% stake in SciSparc Nutraceuticals to Miza, receiving Miza shares and contingent rights that will result in SciSparc holding 75-84% of the renamed 'NeuroThera Labs Inc.' The transaction, which includes an additional commitment of up to CAD1 million in funding for Miza, consolidates SciSparc's pipeline, including treatments for Tourette syndrome and Alzheimer’s disease, into the new entity.

Analysis

SciSparc Ltd. (NASDAQ:SPRC) shares surged 34.5% following the announcement of a definitive agreement to acquire a controlling interest in Miza III Ventures Inc. (TSXV:MIZA.P). This transaction, anticipated to close around October 22, 2025, involves SciSparc transferring its advanced clinical-stage pharmaceutical portfolio and a 51% stake in SciSparc Nutraceuticals to Miza. The market's strongly positive sentiment, indicated by a 0.8 score and bullish tone, reflects approval of this strategic move.

SciSparc will receive 63.3 million Miza common shares and up to 48 million contingent rights, resulting in a post-closing ownership of 75% to 84% in the renamed "NeuroThera Labs Inc." The deal values SciSparc's transferred assets at approximately $11.6 million, significantly higher than Miza's enterprise valuation of $3.3 million, indicating a strategic consolidation of assets into a new, majority-owned entity. This structure effectively spins out SciSparc's key pharmaceutical pipeline, including treatments for Tourette syndrome, Alzheimer’s disease, and autism, into a dedicated vehicle.

Further supporting the new entity, SciSparc or a third party will commit up to CAD1 million (approximately $716,000) to Miza via an unsecured convertible note bearing 7% annual interest. Additionally, SciSparc will receive 4 million Miza common share purchase warrants, exercisable at CAD0.25 over five years, providing potential upside. This financial commitment and the conditional approval from the TSX Venture Exchange underscore the operational intent and potential for future development within the newly structured entity.

Key Decisions for Investors

• Investors should evaluate the strategic benefits of SciSparc consolidating its clinical-stage pharmaceutical assets into the majority-owned NeuroThera Labs Inc. for enhanced focus and potential value unlocking.
• Monitor the transaction's anticipated closing around October 22, 2025, and the successful commitment of the CAD1 million funding, as these are crucial for the new entity's operational stability.
• Assess the long-term clinical development and commercialization prospects of the transferred pipeline assets, including treatments for Tourette syndrome, Alzheimer’s disease, and autism, within the new structure.
• Consider the financial implications of the asset transfer and the new ownership stake on SciSparc's overall valuation and future growth trajectory.